Your browser doesn't support javascript.
New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine.
Nappi, Emanuele; De Santis, Maria; Paoletti, Giovanni; Pelaia, Corrado; Terenghi, Fabrizia; Pini, Daniela; Ciccarelli, Michele; Selmi, Carlo Francesco; Puggioni, Francesca; Canonica, Giorgio Walter; Heffler, Enrico.
  • Nappi E; Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy.
  • De Santis M; IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
  • Paoletti G; Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy.
  • Pelaia C; IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
  • Terenghi F; Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy.
  • Pini D; IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
  • Ciccarelli M; Department of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.
  • Selmi CF; IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
  • Puggioni F; IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
  • Canonica GW; IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
  • Heffler E; Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy.
Vaccines (Basel) ; 10(5)2022 May 03.
Article in English | MEDLINE | ID: covidwho-1820449
ABSTRACT
Anti-SARS-CoV-2 vaccines are safe and effective, also in individuals with allergic and immune-mediated diseases (IMDs). There are reports suggesting that vaccines may be able to trigger de-novo or exacerbate pre-existing IMDs in predisposed individuals. Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, eosinophilia, and eosinophil-rich granulomatous inflammation in various tissues. We describe the case of a 63-year-old man who experienced cardiac, pulmonary, and neurological involvement one day after the administration of the booster dose of anti-SARS-CoV-2 vaccine (mRNA-1273). A diagnosis of EGPA was made and the patient was treated with high-dose steroids and cyclophosphamide, with a good clinical response. Interestingly, our patient had experienced a significant worsening of his pre-existing asthma six months earlier, just after the first two vaccine shots with the ChAdOx1 anti-SARS-CoV-2 vaccine. It is impossible to know whether our patient would have had developed EGPA following natural SARS-CoV-2 infection or at some point in his life regardless of infectious stimuli. Nevertheless, our report may suggest that caution should be paid during the administration of additional vaccine doses in individuals who experienced an increase in IMD severity that persisted over time following previous vaccine shots.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10050716

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10050716